2014 International Achievement Award

The Society annually presents an award to an outstanding individual in recognition of their contributions and achievements in the resolution of public environmental concerns. There are no specific criteria, no age limitations, however, international scientific developments in toxicology are of special interest. 


Jay I. Goodman
Department of Pharmacology and Toxicology
Michigan State University

December 3, 2014

Diane McColl introduction of Dr. Jay I. Goodman,  Ph.D., ATS

I am pleased to announce that Dr. Jay I. Goodman has been awarded the 2014 ISRTP International Achievement Award.

Dr. Goodman is a Professor in the Department of Pharmacology and Toxicology, and Faculty Member, at the Center for Environmental Toxicology, Michigan State University. He is a Diplomate of the American Board of Toxicology and a Fellow of the Academy of Toxicological Sciences.  His research interests are focused on discerning epigenetic mechanisms underlying carcinogenesis and other chemical-induced toxicities, and testing the hypothesis that the capacity to maintain the normal epigenetic status is related inversely to susceptibility to carcinogenesis.

Dr. Goodman has received numerous awards for his scientific achievements, including  the Distinguished Alumnus Award, Doctoral Program in Pharmacology, University of Michigan; the John Barnes Prize Lecture, British Toxicology Society; and the George H. Scott Memorial Award from the Toxicology Forum, among others.  He is also the first American to serve on a EUROTOX committee.  Earlier this year, Dr. Goodman received the SOT Merit Award.

Dr. Goodman has participated actively on numerous SOT Committees and Task Forces, and served as SOT Secretary and SOT President.  He has participated on review panels and advisory boards for the NIH, NIEHS, NSF, NTP, US EPA, CDC, American Board of Toxicology, Academy of Toxicological Sciences, as well as the International Life Sciences Institute, Health and Environmental Sciences Institute. He continues to serve on editorial boards and as an advisor on toxicologic issues.

Dr. Goodman will now offer a few comments on why and how “Toxicology is Part of the Solution.”

Toxicology Is Part Of The Solution (ABSTRACT)

"First, I would like to express my thanks and appreciation to the International Society of Regulatory Toxicology and Pharmacology for awarding me its 2014 International Achievement Award. 

Indeed, I am very proud to receive this honor.  What excites me about research in toxicology is that it combines the theoretical with the practical.  While pursuing research aimed at discerning the mechanism(s) of action of the chemical of interest, we learn more about fundamental aspects of biology. On the practical side, the new knowledge gleaned facilitates the enhancement of science-based safety assessment of chemicals.  In particular, this permits a rational approach towards resolving key issues, e.g., a mechanistic basis for the shape of the dose-response curve (including non-linear, threshold-exhibiting dose-response curves) and appropriate extrapolation from test species to humans. Thus, toxicological research plays a crucial role in enabling the use chemicals (e.g., medicines, consumer products and agricultural chemicals) to enhance the quality of people’s lives and the environment.  In this lecture I will present the salient aspects of my research in the area of “epigenetics meets toxicology.”  In particular, my focus is on understanding the roles that epigenetic alterations play in chemical carcinogenesis, and testing the hypothesis that susceptibility to carcinogenesis is related inversely to the capacity to maintain the normal epigenetic status.  Additionally, I would like to talk about the future of toxicology and the need to embrace the third revolution in the biological sciences, i.e., convergence.  All of my remarks are made within the context of the theme that has guided my scientific career, “toxicology is part of the solution.”

Professor, Pharmacology and Toxicology

Research Interests:
The involvement of mutagenesis in carcinogenesis needs to be reconciled with the fact that not all carcinogens are mutagens and the view that nonmutagenic events also play key roles in the transformation of a normal cell into a cancer cell. This apparent paradox can, in part, be resolved by considering the roles that altered DNA methylation, an epigenetic mechanism, play in carcinogenesis.

Gene expression is not determined only by DNA base sequence; it also depends on epigenetic mechanisms, i.e., heritable gene-regulating mechanisms not involving a change in DNA base sequence. Inheritance occurs on two levels. The transmission of genes either in the somatic sense or from generation to generation is distinct from mechanisms involved in transmission of alternative states of gene activity.

Epigenetics describes the latter and involves regulation of temporal and spatial control of gene activity, e.g., changes in gene expression during development, imprinting, segregation of gene activities such that daughters of a cell exhibit different patterns of gene expression, and mechanisms that permit the somatic inheritance of a specific set of active and quiescent genes.

DNA methylation (the presence of 5-methylcytosine (5MeC) as 5MeC and cytosine base pair with guanine. In general, increased methylation of a gene is associated with deceased transcription (e.g., may silence tumor suppressor genes, functionally equivalent to inactivation due to point mutation or allelic loss) and decreased methylation may up-regulate gene expression (e.g., may increase expression of oncogenes). Thus, altered DNA methylation can facilitate the aberrant gene expression underlying carcinogenesis.

The hypothesis being tested in my laboratory is that susceptibility to carcinogenesis, and perhaps other toxicities, is related inversely to the capacity to maintain normal patterns of DNA methylation. Particular emphasis is being placed on discerning novel genes that are involved in carcinogenesis due to aberrant methylation.

Educational Background:
Long Island University, College of Pharmacy, B.S., 1965
University of Michigan, Ph.D., pharmacology, 1969

Selected Professional Activities:
Dr. Goodman completed postdoctoral training at the University of Wisconsin. He has received the Distinguished Alumnus Award, Long Island University, College of Pharmacy, 1998; was Elected President of the Society of Toxicology, 1999-2000; the Distinguished Alumnus Award, Doctoral Program in Pharmacology, The University of Michigan, 2000; gave the John Barnes Prize Lecture, British Toxicology Society in 2005; and is the recipient of the Society of Toxicology's Merit Award, 2014. Dr. Goodman is a faculty trainer for the NIEHS training grant.



  • (2013) John Fawell, Ph.D.

  • (2012) Michael L. Gargas, Ph.D.

  • (2011) Michael G. Bird, Ph.D., FRSC

  • (2010) Gio Batta Gori, Ph.D.

  • (2009) Michael Dourson, Ph.D., DABT, ATS

  • (2008) Mildred S. Christian, Ph.D., Fellow, ATS

  • (2007) Bernard A. Schwetz, D.V.M., Ph.D. 

  • (2006) Elizabeth I. Anderson, Ph.D.

  • (2005) Jerome H. Heckman, Esq.

  • (2004) Lester M. Crawford, M.D.

  • (2003) Curtis D. Klaassen, Ph.D.

  • (2002) Donald Hughes, Ph.D.

  • (2001) Joseph F. Borzelleca, Ph.D

  • (1999) Dr. Alan Rulis, Director, Office of Premarket Approval (OPA)

  • (1998) Dr. Roger O. McClellan, President, CIIT, Research Triangle Park, NC

  • (1997) Dr. Ian C. Munro, Principal, FRCPath

  • (1996) Dr. John Higginson, Retired Professor of Medicine, Georgetown University

  • (1995) Robert C. Barnard, Esq., Cleary, Gottlieb, Steen & Hamilton

  • (1994) Dr. Philip Abelson, Science Magazine, Washington, DC

  • (1993) Dr. C. Jelleff Carr, Managing Editor of RTP, Columbia, MD

  • (1991) Dr. John P. Frawley, Health & Environment International, Ltd., Wilmington, DE

  • (1990) Dr. John Doull, University of Kansas Medical Center, Kansas City, KS

  • (1989) Dr. Frederick Coulston, Coulston Foundation, Alamogordo, NM

  • (1988) Dr. Robert A. Neal, Retiring President of CIIT, Research Triangle Park, NC

  • (1987) Dr. Gaston A. Vettorazzi, Geneva, Switzerland and Dr. Frank C. Lu, Miami, FL, WHO

© 2014 ISRTP




Hit Counter